Microbiotix
Clinical-stage biopharmaceutical company focused on discovery and development of proprietary small-molecule therapeutics for serious infectious diseases, including multi-drug resistant bacterial pathogens and viral infections. Programs span antiviral nucleoside analogs (clinical-stage) and multiple preclinical antibacterial series targeting novel bacterial mechanisms and resistance pathways. Maintains partnerships with public-private funding and antimicrobial R&D organizations.
Industries
Nr. of Employees
small (1-50)
Patents
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
US-11505533-B2
View Details
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
US-11505533-B2
View DetailsProducts
Lead nucleoside-analog antiviral (clinical-stage; Phase 1 completed)
A nucleoside analog antiviral with dual DNA polymerase and viral kinase inhibition being developed for cytomegalovirus and other ocular viral infections; reported activity versus resistant isolates and completed Phase 1 studies.
Semisynthetic spectinomycin analog series (preclinical)
Spectinomycin-derived analogs (spectinamides and aminospectinomycins) optimized for activity against MDR/XDR tuberculosis, Neisseria gonorrhoeae, Chlamydia and select biodefense pathogens.
Type III secretion system (T3SS) inhibitors (preclinical/lead optimization)
Small-molecule inhibitors targeting the bacterial T3SS needle protein to block toxin delivery and attenuate Pseudomonas aeruginosa virulence for applications such as ventilator-associated pneumonia.
RND efflux pump inhibitor series (preclinical)
Pyranopyridine-type inhibitors of RND-family efflux pumps developed to enhance antibiotic potency as adjunctive therapy against Enterobacteriaceae and other Gram-negative pathogens.
Trans-translation pathway inhibitors (preclinical)
Compounds that inhibit non-stop ribosome rescue (trans-translation), exhibiting broad-spectrum antibacterial activity with oral bioavailability and in vivo efficacy.
Lead nucleoside-analog antiviral (clinical-stage; Phase 1 completed)
A nucleoside analog antiviral with dual DNA polymerase and viral kinase inhibition being developed for cytomegalovirus and other ocular viral infections; reported activity versus resistant isolates and completed Phase 1 studies.
Semisynthetic spectinomycin analog series (preclinical)
Spectinomycin-derived analogs (spectinamides and aminospectinomycins) optimized for activity against MDR/XDR tuberculosis, Neisseria gonorrhoeae, Chlamydia and select biodefense pathogens.
Type III secretion system (T3SS) inhibitors (preclinical/lead optimization)
Small-molecule inhibitors targeting the bacterial T3SS needle protein to block toxin delivery and attenuate Pseudomonas aeruginosa virulence for applications such as ventilator-associated pneumonia.
RND efflux pump inhibitor series (preclinical)
Pyranopyridine-type inhibitors of RND-family efflux pumps developed to enhance antibiotic potency as adjunctive therapy against Enterobacteriaceae and other Gram-negative pathogens.
Trans-translation pathway inhibitors (preclinical)
Compounds that inhibit non-stop ribosome rescue (trans-translation), exhibiting broad-spectrum antibacterial activity with oral bioavailability and in vivo efficacy.
Services
Partnership-based discovery and preclinical development collaborations with public-private funders and antimicrobial development organizations.
Partnership-based discovery and preclinical development collaborations with public-private funders and antimicrobial development organizations.
Expertise Areas
- Antiviral drug development
- Antibacterial discovery and development
- Medicinal chemistry and SAR
- Preclinical in vivo infectious disease models
Key Technologies
- Small-molecule medicinal chemistry
- Nucleoside analog antiviral chemistry
- Protein synthesis inhibition (30S ribosome targeting)
- Type III secretion system (T3SS) inhibition
News & Updates
Announcement of CARB-X funding to support development of an oral antibiotic targeting multidrug-resistant Neisseria gonorrhoeae.
Company presented new preclinical data at the ASM Microbe 2018 conference.
Announcement of a co-development agreement with an antimicrobial R&D center to advance an anti-virulence candidate targeting Pseudomonas aeruginosa in pneumonia patients.
Consistently ranked among top recipients of NIH awards in Massachusetts across multiple years (including first-place rankings in several years).
Announcement of CARB-X funding to support development of an oral antibiotic targeting multidrug-resistant Neisseria gonorrhoeae.
Company presented new preclinical data at the ASM Microbe 2018 conference.
Announcement of a co-development agreement with an antimicrobial R&D center to advance an anti-virulence candidate targeting Pseudomonas aeruginosa in pneumonia patients.
Consistently ranked among top recipients of NIH awards in Massachusetts across multiple years (including first-place rankings in several years).